Written question asked by Lord Mendelsohn (Labour) on Monday, 27 February 2023, in the House of Lords. It was due for an answer on Monday, 13 March 2023. It was answered by Lord Markham (Conservative) on Tuesday, 7 March 2023 on behalf of the Department of Health and Social Care.
Tixagevimab/cilgavimab
- Question
-
To ask His Majesty's Government, further to the Written Answer by Lord Markham on 8 February (HL4944), when the clinical advice that was submitted to the National Institute for Health and Care Excellence (NICE) was agreed by the Therapeutics Clinical Review Panel; and what date was that submitted to NICE.
- Answer
-
The report produced by the Independent Advisory Group on potential cohorts eligible for pre-exposure prophylaxis was reviewed by the Therapeutics Clinical Review Panel in April 2022. It was formally submitted to the National Institute for Health and Care Excellence on 13 January 2023.
Secondary information
- Type
- Written question
- Reference
- HL5938
- Session
- 2022-23
- Related items
- Subjects
- Testing Tixagevimab/cilgavimab
- Link
- View this Written question on www.parliament.uk
Librarians' tools
- Timestamp
- 2024-05-24 10:08:43 +0100
- URI
- http://data.parliament.uk/writtenparliamentaryquestion/lords/2022-23/HL5938
- In Indexing
- http://indexing.parliament.uk/Content/Edit/1?uri=http://data.parliament.uk/writtenparliamentaryquestion/lords/2022-23/HL5938
- In Solr
- https://search.parliament.uk/claw/solr/?id=http://data.parliament.uk/writtenparliamentaryquestion/lords/2022-23/HL5938